Cash injection boosts Amrad R&D program

By Tanya Hollis
Friday, 01 March, 2002

Drug developer Amrad Corporation has raised $15.5 million in capital to help progress its clinical trials program.

The Melbourne company, which this week also revealed early completion of a Phase I/II trial to treat chronic pain, said it had successfully placed 13.5 million ordinary shares at $1.15 per share.

Managing director Dr Sandra Webb said the extra capital would be used to accelerate Amrad's current drug development projects and to a move trials into their later stages.

"Our goal is to build shareholder value by developing drugs to treat chronic human diseases where there is unmet medical need," Webb said.

"This new funding positions Amrad favourably to achieve early commercial returns."

The institutional placement, handled by Intersuisse Corporate, put the company in a better position to negotiate the timing and size of commercialisation deals with major pharmaceutical and biotechnology companies, she said.

Amrad's chronic pain treatment involves a drug called AM336, which is a synthetic version of a molecule originally isolated from the venom of a fish-eating species of cone snail found on the Great Barrier Reef.

In addition, the company is expecting results this month from its Phase II trial of peripheral nerve damage treatment, Emfilermin.

Related News

Organoid platform enables closer study of bat-borne viruses

Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...

Global study finds 250 genes linked to OCD

Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...

TGA approves therapy for paediatric growth hormone deficiency

The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd